Phase 4
Completed N=13
Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT02579772 ↗
Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jun 2018
Primary outcomePrimary: Plasma Redox Status - Circulating Glutathione — 8.97; 7.05 micromolar
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow obstruction.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma Redox Status - Circulating Glutathione |
8.97; 7.05 | — |
| PRIMARY Exercise Capacity - Time to Exhaustion |
336; 325 | — |
| SECONDARY Change in Central Cardiovascular Function - Cardiac Output |
12.5; 12.1 | — |
| SECONDARY Change in Skeletal Muscle Deoxygenation - Dynamics (Mean Response Time) |
19.0; 19.0 | — |
| SECONDARY Change in Skeletal Muscle Vascular Function - Capillary Blood Flow Dynamics (Mean Response Time) |
65.4; 66.5 | — |
| SECONDARY Change in Pulmonary Oxygen Uptake - Dynamics (Mean Response Time) |
63.0; 62.2 | — |
| SECONDARY Change in Pulmonary Ventilation - Minute Ventilation (VE) |
78.7; 75.8 | — |
Eligibility Criteria
Inclusion Criteria
- stable COPD with mild-to-moderate airflow obstruction as indicated by the low ratio between forced expiratory volume in one second and forced vital capacity (FEV1/FVC 35kg/m²);
- other diagnosed cardiorespiratory disorders (e.g., chronic heart failure, peripheral artery disease).
Data sourced from ClinicalTrials.gov (NCT02579772). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.